NCT00332176 - A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Chronic Hepatitis C

Interventions

DRUG

Celgosivir

400mg qd + standard of care for 12 weeks

DRUG

Celgosivir

600mg qd + standard of care for 12 weeks

DRUG

Peginterferon alfa 2b + ribavirin

Standard of care for 12 weeks

Trial Locations (3)

RECRUITING

Liver and Intestinal Research Centre, Vancouver

COMPLETED

Cantest, Vancouver

RECRUITING

Biovail Contract Research, Toronto